Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Lung Cancer

  Free Subscription


12.01.2026

1 AJR Am J Roentgenol
2 Am J Epidemiol
6 Ann Surg Oncol
3 BMC Cancer
3 Br J Cancer
1 Cancer Chemother Pharmacol
2 Cancer Lett
1 Cancer Sci
3 Clin Lung Cancer
2 Clin Nucl Med
1 Eur J Cancer
1 Eur J Cardiothorac Surg
2 J Cancer Res Clin Oncol
1 J Clin Oncol
1 J Nucl Med
2 Lung Cancer
1 Mol Carcinog
1 Nat Med
1 Oncogene
1 Oncol Rep
3 PLoS One
1 Thorax


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. STRICKLAND LR, Tailor TD
    Digital Outreach as a Lever to Improve Lung Cancer Screening Rates.
    AJR Am J Roentgenol. 2026 Jan 7. doi: 10.2214/AJR.25.34447.
    PubMed        


    Am J Epidemiol

  2. DEBONO NL, Everest L, Richardson DB, Berriault C, et al
    Impact of interventions to prevent asbestos-related respiratory disease in an exposed worker registry using a simplified G-computation.
    Am J Epidemiol. 2026;195:92-101.
    PubMed         Abstract available

  3. HAN G, Schell MJ, Smith ML, Hopkins L, et al
    Determining the threshold time in restricted mean survival time analysis for two group comparisons with applications in clinical and epidemiology studies.
    Am J Epidemiol. 2026;195:32-39.
    PubMed         Abstract available


    Ann Surg Oncol

  4. LI Z, Shen Y, Dai J, Jin K, et al
    Risk Factors for Postoperative Acute Exacerbations and Long-Term Survival in Patients with Concomitant Lung Cancer and Idiopathic Pulmonary Fibrosis.
    Ann Surg Oncol. 2026 Jan 9. doi: 10.1245/s10434-025-18877.
    PubMed         Abstract available

  5. JUNG W, Cho S, Jeon JH, Kim K, et al
    Percutaneous Transthoracic Needle Biopsy May Increase Recurrence in Early-Stage Non-Small Cell Lung Cancer: A Propensity Score-Matched Analysis.
    Ann Surg Oncol. 2026 Jan 9. doi: 10.1245/s10434-025-18820.
    PubMed         Abstract available

  6. ZHOU H, Lei J, Liao J, Wang Y, et al
    Symptom Cluster Trajectories of Cough, Shortness of Breath, and Disturbed Sleep in Patients Undergoing Lung Cancer Surgery: A Longitudinal Study.
    Ann Surg Oncol. 2026 Jan 6. doi: 10.1245/s10434-025-18994.
    PubMed         Abstract available

  7. CHEN W, Xue X, Ma J, Li Y, et al
    Personalized Conditional Survival Prediction for Patients with Early-Stage Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2026 Jan 6. doi: 10.1245/s10434-025-18785.
    PubMed         Abstract available

  8. JUNG W, Cho S
    ASO Author Reflections: Reconsidering the Role of Preoperative Biopsy in Early Stage Lung Cancer: It Could Be a Risk.
    Ann Surg Oncol. 2026 Jan 6. doi: 10.1245/s10434-025-18948.
    PubMed        

  9. KANZAKI R, Chikaraishi H, Samejima H, Kobayashi M, et al
    Differential Diagnosis of Solitary Pulmonary Nodules in Postoperative Pancreatic Cancer Patients Using KRAS Gene Mutation Analysis.
    Ann Surg Oncol. 2026;33:1806-1816.
    PubMed         Abstract available


    BMC Cancer

  10. XIA T, Zhang QX, Liu C, Wang ML, et al
    Elevated levels of SLC38A1 are correlated with an unfavorable prognosis, as well as accelerated cell proliferation and metastasis in lung adenocarcinoma.
    BMC Cancer. 2026;26:20.
    PubMed         Abstract available

  11. SHAO J, Zhang B, Yang S, Jin P, et al
    Patient preference for first-line treatments of ALK-positive metastatic non-small cell lung cancer: a discrete choice experiment.
    BMC Cancer. 2026 Jan 5. doi: 10.1186/s12885-025-15509.
    PubMed        

  12. ZHENG T, Li X, Jin J, Zhou L, et al
    Association of HMGB1 expression with prognosis of non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2026 Jan 5. doi: 10.1186/s12885-025-15508.
    PubMed         Abstract available


    Br J Cancer

  13. ROSEN JC, Cao P, Pham NA, Waas M, et al
    Modeling response to the KRAS-G12C inhibitor AZD4625 in KRAS(G12C) NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms.
    Br J Cancer. 2026;134:165-174.
    PubMed         Abstract available

  14. DE RUITER JC, van der Noort V, van Diessen JNA, Smit EF, et al
    Stage I non-small cell lung cancer: improving patient selection for minimally invasive lobectomy or stereotactic ablative radiotherapy based on clinical characteristics.
    Br J Cancer. 2026 Jan 8. doi: 10.1038/s41416-025-03332.
    PubMed         Abstract available

  15. GALAL B, Dennis J, Antoniou AC, Harrison H, et al
    The current state of polygenic scores for the development of lung cancer: a systematic review and validation in UK Biobank.
    Br J Cancer. 2026 Jan 8. doi: 10.1038/s41416-025-03330.
    PubMed         Abstract available


    Cancer Chemother Pharmacol

  16. HUANG H, Wang J
    Association between modifications in intravenous chemotherapy dose and disease-free survival and related influencing factors in lung cancer patients: a retrospective study based on inverse probability weighting.
    Cancer Chemother Pharmacol. 2026;96:6.
    PubMed         Abstract available


    Cancer Lett

  17. LI Y, Li C, Wang Y, Zhou J, et al
    Mitigating tumor heterogeneity in lung Cancer: A dual-targeted NIR-II imaging strategy for accurate tumor localization and intraoperative navigation.
    Cancer Lett. 2026;640:218241.
    PubMed         Abstract available

  18. HUANG Y, Wei Z, Ye G, Cui Y, et al
    Automated CT-derived Body Composition Predicts Pathologic Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
    Cancer Lett. 2026 Jan 6:218229. doi: 10.1016/j.canlet.2025.218229.
    PubMed         Abstract available


    Cancer Sci

  19. SATO S, Yilmaz N, Arai S, Sakai K, et al
    MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity.
    Cancer Sci. 2026;117:118-129.
    PubMed         Abstract available


    Clin Lung Cancer

  20. KATAOKA S, Shukuya T, Ohtsu H, Miyawaki T, et al
    Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L.
    Clin Lung Cancer. 2025 Dec 9:S1525-7304(25)00330.
    PubMed         Abstract available

  21. OE K, Saruwatari K, Miyasato Y, Kakizoe Y, et al
    Selpercatinib-Associated Nephropathy in RET Fusion-Positive Lung Cancer: A Case Successfully Managed With Dose Adjustment and Nephroprotective Therapy.
    Clin Lung Cancer. 2025;27:1-5.
    PubMed        

  22. VIDETIC GMM, Fleming CW, Reddy CA, Stephans KL, et al
    Lung SBRT Outcomes for Inoperable Early-Stage Lung Cancer Are Impaired in Patients With Solid Organ Transplants.
    Clin Lung Cancer. 2025;27:6-13.
    PubMed         Abstract available


    Clin Nucl Med

  23. PUROHIT P, Preet K, Mittal BR, Kumar R, et al
    Rare Presentation of Lymphomatoid Granulomatosis With CNS, Pulmonary, and Musculoskeletal System Involvement on 18F-FDG PET/CT.
    Clin Nucl Med. 2025 Sep 26. doi: 10.1097/RLU.0000000000005944.
    PubMed         Abstract available

  24. PUROHIT P, Aggarwal P, Kumar R, Preet K, et al
    Exploring the Diagnostic Utility of 68Ga-FAPI-46 PET/CT in Diverse Pulmonary Pathologies: A Comparative Analysis With 18F-FDG PET/CT.
    Clin Nucl Med. 2025 Oct 24. doi: 10.1097/RLU.0000000000006186.
    PubMed         Abstract available


    Eur J Cancer

  25. PLAZY C, Boussena M, Nguyen Phuong L, Assie JB, et al
    The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy.
    Eur J Cancer. 2026;232:116115.
    PubMed         Abstract available


    Eur J Cardiothorac Surg

  26. HURLEY PD, Chaudhuri N, Lodhia J, Milton R, et al
    Risk Factors Associated With Locoregional Recurrence Following Pulmonary Segmentectomy for Clinical Stage IA1-2 NSCLC: A Real Clinical Practice Analysis.
    Eur J Cardiothorac Surg. 2026;68:ezaf442.
    PubMed         Abstract available


    J Cancer Res Clin Oncol

  27. LIU Y, Wang F, Wang P, Zhou Z, et al
    AI-MDT: an automatic and intelligent multidisciplinary team consultations platform for lung cancer diagnosis.
    J Cancer Res Clin Oncol. 2026;152:32.
    PubMed         Abstract available

  28. DING T, Xie Y, Ding M
    Therapeutic progress in leptomeningeal metastasis from EGFR mutant non-small cell lung cancer: a clinical medicine review.
    J Cancer Res Clin Oncol. 2026;152:38.
    PubMed         Abstract available


    J Clin Oncol

  29. BRADLEY JD, Sugawara S, Lee KH, Ostoros G, et al
    Erratum: Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.
    J Clin Oncol. 2026 Jan 7:JCO2503012. doi: 10.1200/JCO-25-03012.
    PubMed        


    J Nucl Med

  30. CHRISTENSEN TN, Langer SW, Dejanovic D, Gillings N, et al
    Malignancy Detection Rates of [(68)Ga]Ga-SSO120 PET/CT in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Lung Cancer.
    J Nucl Med. 2026 Jan 8:jnumed.125.270233. doi: 10.2967/jnumed.125.270233.
    PubMed         Abstract available


    Lung Cancer

  31. ZHOU DD, Lord SJ, Lin FP, Cooper WA, et al
    Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials.
    Lung Cancer. 2025;212:108891.
    PubMed         Abstract available

  32. LIU G, Abrahami D, Ramachandran P, Messina R, et al
    Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors.
    Lung Cancer. 2025;212:108858.
    PubMed         Abstract available


    Mol Carcinog

  33. REDDY JP, Clague RA, Peixoto BP, Bernstein S, et al
    Lung Cancer Cells Secrete Glutamine to Accumulate Tumor-Associated Macrophages.
    Mol Carcinog. 2026 Jan 7. doi: 10.1002/mc.70077.
    PubMed         Abstract available


    Nat Med

  34. LI Z, Li Y, Xiang J, Wang X, et al
    AI-enabled virtual spatial proteomics from histopathology for interpretable biomarker discovery in lung cancer.
    Nat Med. 2026 Jan 5. doi: 10.1038/s41591-025-04060.
    PubMed         Abstract available


    Oncogene

  35. WANG W, He Q, Fan T, Xiong Y, et al
    An H4K12la/CEBPB-AKR1C2 signaling axis modulates the mTOR pathway to regulate cisplatin resistance in lung cancer.
    Oncogene. 2026 Jan 7. doi: 10.1038/s41388-025-03669.
    PubMed         Abstract available


    Oncol Rep

  36. SHARMA U, Song J, Kandu H, Zhu Y, et al
    Advances in targeting KRAS mutations: A promising approach for the treatment of non?small cell lung cancer (Review).
    Oncol Rep. 2026;55:39.
    PubMed         Abstract available


    PLoS One

  37. SHWEIKEH E, Al-Rajab M, Lu J, Xu Q, et al
    A deep learning model to enhance lung cancer detection using 'Dual-Branch' model classification approach.
    PLoS One. 2026;21:e0339404.
    PubMed         Abstract available

  38. LI Y, Wu J, Long M, Zeng T, et al
    Prediction of differentiation levels in lung adenocarcinoma using peripheral blood inflammatory cytokines and tumor markers.
    PLoS One. 2026;21:e0339414.
    PubMed         Abstract available

  39. ZHOU Y, Wang B, Song C, Xie W, et al
    Identification of ACE and HSPB8 as novel drug targets for LUSC treatment and prognosis based on a prognostic model integrating epigenetic regulation and endoplasmic reticulum stress-related genes.
    PLoS One. 2026;21:e0335395.
    PubMed         Abstract available


    Thorax

  40. EVISON M, Naylor R, Malcolm R, Holmes H, et al
    Health economic model to evaluate the cost-effectiveness of smoking cessation services integrated within lung cancer screening in the United Kingdom.
    Thorax. 2026 Jan 6:thorax-2024-222815. doi: 10.1136/thorax-2024-222815.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.